
Opinion|Videos|April 11, 2025
Disease Progression in DLBCL: Management Strategies and Quality-of-Life Considerations
Experts discuss how disease progression impacts patients with diffuse large B-cell lymphoma (DLBCL) and strategies for managing progressive disease based on first-line therapy selection, incorporating insights from the POLARIX 5-year subsequent treatment data and highlighting quality-of-life considerations that influence treatment decisions.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please describe how disease progression impacts patients with DLBCL and the approaches to managing progressive disease based on first-line therapy selection.
• How do the POLARIX 5-year subsequent treatment data inform your approach, and what quality-of-life considerations influence your treatment approach?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















